In addition, the use of renin-angiotensin-aldosterone (RAAS) inhibitors and recently approved drugs, such as SGLT2 inhibitors, are widely recognized as one of the most effective methods for delaying the progression of the disease in early CKD [25–27]. Here, SLC5A2 is linked to chronic kidney disease.